Literature DB >> 2890522

The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Lopressor Intervention Trial Research Group.

.   

Abstract

The Lopressor Intervention Trial (LIT) was a double-blind, randomized, placebo-controlled, multicentre study designed to evaluate the effect of oral metoprolol on overall mortality in patients surviving a recent acute myocardial infarction. Patient enrollment began in August 1979 and ended on 15 April 1982, with 2395 patients (1200 on placebo and 1195 on metoprolol). Hospitalized patients, 45 to 74 years of age, began therapy from 6 to 16 days after their myocardial infarction. Following a short titration period, maintenance therapy with metoprolol 100 mg b.i.d. or placebo was continued for up to 1 year. Enrollment was prematurely terminated because of a progressive and marked decline in patient accession; it was not feasible to reach the original goal of 3200 patients in a practical period of time. This target sample size was based on an anticipated 1 year placebo mortality rate of 10%, a 50% reduction in total mortality with metoprolol and premature discontinuation of study medication in no more than 15% of patients in the metoprolol group. Two primary analyses were planned: total mortality among all randomized patients at 7 and at 12 months of trial entry. After 7 months of treatment there were 54 deaths in the placebo group and 42 deaths in the metoprolol group. After 1 year there were 62 deaths in the placebo group and 65 in the metoprolol group. Thus, the 1 year placebo mortality rate of 5.2% was half that predicted at the outset. In addition, study medication was prematurely discontinued in over 30% of patients in the metoprolol group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890522

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  10 in total

Review 1.  Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 2: Beta-blockers.

Authors:  J M Wright
Journal:  CMAJ       Date:  2000-07-25       Impact factor: 8.262

Review 2.  An overview of therapeutic interventions in myocardial infarction. Emphasis on secondary prevention.

Authors:  V Hinstridge; T M Speight
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 3.  When is drug therapy warranted to prevent sudden cardiac death?

Authors:  B N Singh
Journal:  Drugs       Date:  1991       Impact factor: 9.546

4.  Calcium antagonists in secondary prevention after myocardial infarction.

Authors:  S Persson
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 5.  Calcium antagonists during and after myocardial infarction.

Authors:  P Sleight
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

Review 6.  Beta-blockers in patients without heart failure after myocardial infarction.

Authors:  Sanam Safi; Naqash J Sethi; Steven Kwasi Korang; Emil Eik Nielsen; Joshua Feinberg; Christian Gluud; Janus C Jakobsen
Journal:  Cochrane Database Syst Rev       Date:  2021-11-05

7.  Type of β-blocker use among patients with versus without diabetes after myocardial infarction.

Authors:  Suzanne V Arnold; John A Spertus; Kasia J Lipska; David E Lanfear; Fengming Tang; Anna Grodzinsky; Darren K McGuire; M Odette Gore; Abhinav Goyal; Thomas M Maddox; Mikhail Kosiborod
Journal:  Am Heart J       Date:  2014-06-09       Impact factor: 4.749

Review 8.  β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature.

Authors:  James J DiNicolantonio; Hassan Fares; Asfandyar K Niazi; Saurav Chatterjee; Fabrizio D'Ascenzo; Enrico Cerrato; Giuseppe Biondi-Zoccai; Carl J Lavie; David S Bell; James H O'Keefe
Journal:  Open Heart       Date:  2015-03-21

9.  Comparison of Metoprolol Versus Carvedilol After Acute Myocardial Infarction.

Authors:  Ghaith Zaatari; Dan J Fintel; Haris Subacius; Joseph J Germano; Jacob Shani; Jeffrey J Goldberger
Journal:  Am J Cardiol       Date:  2021-02-20       Impact factor: 2.778

Review 10.  Beta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it "ok" to discontinue?

Authors:  Anna Kezerashvili; Kevin Marzo; Joshua De Leon
Journal:  Curr Cardiol Rev       Date:  2012-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.